LoVo Xenograft Rat Model Service for Colon Cancer

The LoVo xenograft rat model captures the molecular complexity of metastatic colorectal adenocarcinoma—including MSI-high status and KRAS G13D mutation—within an immunodeficient rat host that supports robust tumor engraftment and pharmacokinetic profiling. Alfa Cytology constructs this model using authenticated ATCC CCL-229 cell stocks and standardized nude rat implantation protocols, delivering reproducible tumor kinetics and comprehensive endpoint analytics that advance your early-stage colon cancer therapeutic program from target validation through preclinical candidate selection.

Overview of LoVo Xenograft Rat Model for Colon Cancer

The LoVo cell line was originally isolated in 1971 from a metastatic tumor nodule in the left supraclavicular region of a 56-year-old male patient diagnosed with grade IV Dukes C colorectal adenocarcinoma. As a human-derived epithelial line, LoVo requires an immunocompromised host for xenograft establishment, and immunodeficient nude rats provide an advantageous preclinical chassis—offering larger blood volumes for serial pharmacokinetic sampling, expanded tissue availability for biomarker analysis, and surgical accessibility for orthotopic cecal implantation. The line is characterized by microsatellite instability–high (MSI-H) status, a KRAS G13D activating mutation, wild-type BRAF, and truncating APC variants, collectively mirroring the molecular signature of a clinically relevant subset of advanced colorectal cancers.

Fig 1. Comparative Schematics of Established Murine Colorectal Cancer Models. (Al-Kabani, Ahad, et al., 2025)

In xenograft settings, LoVo tumors retain glandular architecture with cribriform and tubular patterns, produce carcinoembryonic antigen (CEA), and exhibit a doubling time of approximately 37 hours in vitro. The model has proven responsive to cytotoxic agents such as oxaliplatin and 5-fluorouracil while displaying upregulation of thymidylate synthase and ABC transporters that parallel clinical resistance mechanisms. Beyond subcutaneous flank implantation, LoVo cells can be introduced orthotopically into the cecal wall to model primary tumor–liver metastasis progression, or engineered as cancer stem cell–enriched spheroids to interrogate drug resistance and tumor-initiating capacity. These attributes position the LoVo xenograft rat model as a versatile backbone for evaluating small-molecule inhibitors, antibody-drug conjugates, and nanoparticle-based delivery systems in colorectal oncology.

Cell Line Information: LoVo

The table below summarizes the authenticated characteristics of the LoVo human colorectal adenocarcinoma cell line, compiled from ATCC repository data, ECACC records, and peer-reviewed literature.

Our Services

Alfa Cytology bridges the gap between in vitro LoVo characterization and in vivo translational outcomes by managing every stage of xenograft construction—from authenticated cell banking and Matrigel-assisted implantation into immunodeficient rats through longitudinal tumor monitoring, blood chemistry analysis, and terminal histopathology with quantitative biomarker readouts. Each study is tailored to your compound's mechanism of action and conducted under accredited IACUC oversight with full GLP-aligned documentation, ensuring data integrity and regulatory readiness for IND-enabling packages.

Workflow of LoVo Xenograft Rat Model Construction

Construction of the LoVo xenograft rat model follows a standardized yet adaptable workflow designed to achieve high tumor take rates, consistent growth kinetics, and robust pharmacodynamic endpoints. The protocol supports both subcutaneous flank and orthotopic cecal implantation routes, selected according to the mechanistic and therapeutic objectives of the sponsor.

1. Cell Line Resuscitation & Expansion: Cryopreserved LoVo stocks (ATCC CCL-229) are thawed and expanded in complete growth medium under antibiotic-free, low-passage conditions. Cell identity is verified by morphology, growth curve analysis, and STR profiling against the authenticated reference profile. Harvest occurs at 70–80% confluence using 0.05% trypsin-EDTA; viability is confirmed by trypan blue exclusion, with only suspensions exceeding 98% viability advanced to implantation. For subcutaneous studies, cells are resuspended in serum-free medium at 1 × 10⁷ cells/mL and mixed 1:1 with cold Matrigel (50 µL final volume per injection).
2. Host Selection & Acclimation: Immunodeficient nude rats (e.g., Hsd:RH-Foxn1rnu, 6–8 weeks old, 150–200 g) are ordered from accredited vendors and acclimated for 7–10 days under specific-pathogen-free conditions. Baseline body weights are recorded, and animals are screened for clinical abnormalities prior to enrollment. The larger body mass of rats relative to mice facilitates serial blood draws (up to 200–300 µL per collection) for pharmacokinetic and pharmacodynamic profiling without compromising hemodynamic stability.
3. Tumor Cell Implantation: For subcutaneous models, 100 µL of the LoVo-Matrigel suspension (1 × 10⁶ cells) is injected into the right flank using a 25-gauge needle. For orthotopic cecal models, a midline laparotomy is performed under isoflurane anesthesia; the cecum is exteriorized, and 50 µL of cell suspension (5 × 10⁵ cells) is injected into the cecal wall subserosally using a 30-gauge Hamilton syringe. The injection site is sealed with surgical adhesive, the cecum is returned to the abdominal cavity, and the incision is closed in two layers with absorbable suture.
4. Post-Operative Monitoring & Tumor Tracking: Animals recover on heated pads with continuous respiratory monitoring. Analgesia (buprenorphine, 0.05 mg/kg) is administered for 48 hours post-surgery. Subcutaneous tumors are measured twice weekly with digital calipers (volume = L × W² / 2) from the first palpable detection. Orthotopic tumors are monitored by longitudinal ultrasound or bioluminescence imaging (for luciferase-transduced LoVo variants) starting at day 10 post-implantation. Body weights and clinical signs are recorded throughout.
5. Therapeutic Intervention & Endpoint Harvest: Upon reaching the target tumor volume (typically 100–200 mm³ for subcutaneous; 50–100 mm³ for orthotopic by imaging), animals are randomized into treatment and vehicle control cohorts. Test articles are administered via the sponsor-specified route—intravenous, intraperitoneal, oral gavage, or intratumoral—according to the dosing regimen. Tumor measurements continue on schedule until study endpoint, at which time animals are humanely euthanized. Tumors, liver, lungs, mesenteric lymph nodes, and blood are harvested. Tumor weight is recorded, tissues are digitally imaged, and samples are snap-frozen, fixed in formalin, or submerged in RNAlater for downstream molecular, histopathological, and pharmacokinetic analyses.

Fig 2. LoVo Xenograft Rat Model construction workflow.

Case Study-LoVo Xenograft Rat Model Development

In a recent preclinical engagement, Alfa Cytology utilized the LoVo subcutaneous xenograft rat model to evaluate the antitumor activity of a novel topoisomerase I inhibitor formulated as PEG-PBLG nanoparticles. Following authenticated LoVo cell expansion and Matrigel-assisted implantation into nude rats, tumors were permitted to establish for 14 days prior to randomization into vehicle, free drug, and nanoparticle-encapsulated drug cohorts. The nanoparticle formulation was administered intravenously on a biweekly schedule, with longitudinal tumor volume monitoring and interim body-weight assessments. Terminal analyses included H&E histopathology, Ki-67 proliferation index, TUNEL apoptosis scoring, and plasma drug-concentration profiling. The dataset revealed a marked improvement in tumor growth inhibition and extended plasma half-life relative to the free drug arm, providing the sponsor with pharmacokinetic and pharmacodynamic evidence to support formulation optimization and downstream toxicology planning.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your preclinical partner for LoVo colon cancer model development means accessing a specialized infrastructure that combines authenticated cell biology, immunodeficient rat surgical expertise, and integrated analytical capabilities.

• Authenticated LoVo master and working cell banks are maintained under documented low-passage protocols with periodic STR verification to ensure mutational fidelity and consistent tumorigenicity in immunodeficient rats.
• Our surgical team is proficient in both subcutaneous flank and orthotopic cecal implantation techniques in nude rats, achieving high tumor take rates with minimal perioperative mortality through refined anesthesia and post-operative care.
• The larger physiological scale of rats enables serial blood sampling for pharmacokinetic profiling, expanded tissue harvest for multi-omics analysis, and surgical accessibility for intratumoral dosing or device implantation.
• Integrated endpoint packages span standard caliper-based tumor tracking through to advanced histopathology, CEA quantification, microvessel density scoring, and multiplex cytokine profiling, collapsing the timeline from study completion to data delivery.
• Study protocols are customized to your therapeutic modality—whether small-molecule cytotoxics, antibody-drug conjugates, nanoparticle formulations, or immune-oncology agents—with clear go/no-go decision criteria built into the design.
• All in vivo work is conducted under fully accredited IACUC oversight with real-time veterinary monitoring and GLP-aligned documentation, ensuring ethical integrity and generating audit-ready data packages for regulatory submissions.

Contact Us

If your colorectal cancer therapeutic pipeline demands a preclinical model that faithfully recapitulates MSI-high molecular biology and metastatic adenocarcinoma behavior within an immunodeficient rat host, reach out to us to discuss how Alfa Cytology can architect a LoVo xenograft study aligned with your development milestones. Our scientific team will review your target profile, propose a customized protocol with integrated pharmacokinetic and biomarker endpoints, and deliver a comprehensive proposal within two business days. Contact us today and move your colon cancer program from bench to preclinical proof-of-concept with confidence.

For research use only. Not intended for any clinical use.